Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test

Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test

MADISON, Wis.--(BUSINESS WIRE)--Apr 22, 2025-

Oncodetect MRD Detection Aids Treatment Decision-Making in CRC and Other Solid Tumors: With Eric Christenson, MD

Dr Christenson discusses the capabilities of the Oncodetect test, its clinical applications and pronostic value, and findings from the Alpha-CORRECT study.

Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions - Life Sciences British Columbia

Labcorp, a global leader of innovative and comprehensive laboratory services, announced the expansion of its precision oncology portfolio.

Exact Sciences Enters the MRD Fray With a Hot Prospect

Molecular residual disease (MRD) detection is a practice-changing field, and Exact Sciences has just launched a potential breakthrough entrant. The test is first being used in colorectal cancer (CRC), but there are plans to expand its use to other solid tumors. Rick Baehner, chief medical officer of precision oncology at Exact Sciences, told Inside Precision Medicine that the Oncodetect test answers one of the key questions oncologists have: “Sh…

In Business: Exact Sciences launches Oncodetect test for lingering cancerous cells - Wisconsin Technology Council

Exact Sciences Corp., which provides cancer screening and diagnostic tests, on Tuesday announced the launch of Oncodetect — a new test designed to detect molecular residual disease (MRD) across multiple solid tumors. The Oncodetect test provides patients and their health care providers with the insights needed to make more informed decisions throughout the treatment process.

Exact Sciences launches Oncodetect test for lingering cancerous cells

The test provides patients and their health care providers with the insights needed to make more informed decisions throughout the treatment process.